Veronica Anania
Principal Scientist Development, OMNI Biomarker Development
"I am extremely grateful to work with such dedicated and passionate scientists to answer important questions that may improve the lives of patients."
I joined Genentech in 2011 as a postdoctoral researcher of Jennie Lill who leads the Proteomics and Biological Resources group. As a member of the proteomics group I used mass spectrometry to investigate post-translational modifications and to identify biomarkers of cell death. During this time I was fortunate to work on many independent and collaborative projects that highlighted the numerous applications of this rapidly evolving technology. In 2014 I was hired as a Scientist in Biomarker Development to lead a group focused on applying mass spectrometry-based approaches to interrogate biomarker hypotheses in our clinical programs. I am privileged to have access to state-of-the-art equipment, incredibly knowledgeable colleagues, and clinical samples that enable us to answer challenging biomarker questions that provide insight into underlying disease mechanisms.
Featured Publication
Uncovering a Dual Regulatory Role for Caspases During Endoplasmic Reticulum Stress-induced Cell Death.
Mol Cell Proteomics. 2016 Jul;15(7):2293-307.